Business Context and Reporting Period
This Form 8-K Current Report from IMMUNIC, INC. covers events occurring on June 29, 2026, with the report dated July 6, 2026. The filing addresses corporate governance changes involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Resignation: Tamar Howson resigned as a member of the Board of Directors and the Compensation Committee on June 29, 2026, to transition into retirement.
- Reason for Departure: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Appointment: On July 5, 2026, the Board appointed Erik Lundgren, the Company's Chief Executive Officer, as a Class II director.
- Term: Mr. Lundgren's term will last until the 2028 annual meeting of stockholders or until his successor is elected, qualified, or until earlier death, resignation, or removal.
Guidance, Outlook, and Management Commentary
- Compensation: Mr. Lundgren will not receive additional compensation for his service as a director, as he is already compensated under his existing employment agreement as CEO.
- Committee Service: Mr. Lundgren has not been appointed to serve on any Board committee.
- Related Transactions: There are no arrangements or understandings between Mr. Lundgren and any other person regarding his appointment. No other transactions involving Mr. Lundgren require disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Tamar Howson's resignation (June 29, 2026).
- Confirm Erik Lundgren's new role as a Class II director and his term end date (2028 annual meeting).
- Review the prior Form 8-K filed on May 27, 2026, for details on Mr. Lundgren's CEO employment agreement.
- Confirm that no additional director compensation is being paid to Mr. Lundgren.